Recombinant truncated latency-associated peptide alleviates liver fibrosis in vitro and in vivo via inhibition of TGF-β/Smad pathway.
Xudong SongJiayi ShiJieting LiuYong LiuYang YuYufei QiuZhiqin CaoYu PanXiaohuan YuanYanhui ChuDan WuPublished in: Molecular medicine (Cambridge, Mass.) (2022)
LAP and tLAP could alleviate liver fibrosis in vitro and in vivo via inhibition of TGF-β/Smad pathway. TLAP has higher expression level and more effective anti-fibrosis activity compared to LAP. This study may provide new ideas for the treatment of liver fibrosis.